DK0495896T3 - Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel - Google Patents

Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel

Info

Publication number: DK0495896T3
Authority: DK; Denmark
Prior art keywords: hiv; infections; protection against; vaccine; preparation
Prior art date: 1989-10-14

Application number

DK90915992.3T

Other languages

English (en)

Inventor

Ursula Dietrich

Michalina Adamski

Hagen Von Briesen

Herbert Kuehnel

Helga Ruebsamen-Waigmann

Original Assignee

Chemotherapeutisches Forschungsinstitut Georg Speyer Haus

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-10-14

Filing date

1990-10-12

Publication date

1994-10-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6391493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0495896(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-10-12 Application filed by Chemotherapeutisches Forschungsinstitut Georg Speyer Haus filed Critical Chemotherapeutisches Forschungsinstitut Georg Speyer Haus

1994-10-10 Application granted granted Critical

1994-10-10 Publication of DK0495896T3 publication Critical patent/DK0495896T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

DK90915992.3T 1989-10-14 1990-10-12 Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel DK0495896T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3934366A DE3934366A1 (de)	1989-10-14	1989-10-14	Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum

Publications (1)

Publication Number	Publication Date
DK0495896T3 true DK0495896T3 (da)	1994-10-10

Family

ID=6391493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK90915992.3T DK0495896T3 (da)	1989-10-14	1990-10-12	Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel

Country Status (8)

Country	Link
US (1)	US5861243A (da)
EP (1)	EP0495896B1 (da)
JP (1)	JP3152433B2 (da)
AT (1)	ATE106748T1 (da)
DE (2)	DE3934366A1 (da)
DK (1)	DK0495896T3 (da)
ES (1)	ES2055922T3 (da)
WO (1)	WO1991005567A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL98845A0 (en) *	1990-07-19	1992-07-15	Merck & Co Inc	Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
US5274122A (en) *	1992-10-15	1993-12-28	Merck & Co., Inc.	Acidic derivatives of homocysteine thiolactone
PT787191E (pt) *	1994-10-20	2007-12-06	Pasteur Institut	Sequências nucleotídicas de antigénios retroviraisde vih do tipo (ou sub-tipo) o
US6124262A (en) *	1995-03-17	2000-09-26	The Regents Of The University Of California	Compositions and methods for reducing adhesiveness of defective red blood cells
US6426412B1 (en) *	1995-12-20	2002-07-30	Subsidiary No. 3, Inc.	Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
US7144699B2 (en) *	1997-03-20	2006-12-05	Affymetrix, Inc.	Iterative resequencing
US5891994A (en) *	1997-07-11	1999-04-06	Thymon L.L.C.	Methods and compositions for impairing multiplication of HIV-1
EP1165798A2 (en)	1999-03-29	2002-01-02	Statens Serum Institut	Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
EP1178825B1 (en)	1999-05-13	2011-07-13	Wyeth Holdings Corporation	Adjuvant combination formulations
DK1240186T3 (da) *	1999-12-23	2010-05-31	Medical Res Council	Forbedringer i eller relateret til immunrespons mod HIV
US6399067B1 (en) *	2000-04-28	2002-06-04	Thymon L.L.C.	Methods and compositions for impairing multiplication of HIV-1
HUP0600589A2 (en) *	2000-11-10	2006-11-28	Wyeth Corp	Adjuvant combination formulations
US8076060B2 (en) *	2003-08-04	2011-12-13	Emil William Chynn	Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
WO2006088740A2 (en)	2005-02-15	2006-08-24	Thymon, L.L.C.	Methods and compositions for impairing multiplication of hiv-1
US20100275278A1 (en) *	2006-02-03	2010-10-28	Karp Nelson M	Animal model for hiv induced disease
CN102123724B (zh)	2008-06-19	2018-05-01	变异生技公司	治疗流行性感冒的组合物和方法
WO2011005772A1 (en)	2009-07-06	2011-01-13	Variation Biotechnologies, Inc.	Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en)	2009-07-06	2015-06-04	Variation Biotechnologies, Inc.	Methods for preparing vesicles and formulations produced therefrom
EP2590674B1 (en)	2010-07-06	2017-02-22	Variation Biotechnologies Inc.	Compositions and methods for treating influenza
EP2663327A4 (en)	2011-01-13	2015-12-02	Variation Biotechnologies Inc	COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
ES2667425T3 (es)	2011-06-10	2018-05-10	Oregon Health & Science University	Glucoproteínas y vectores recombinantes de CMV
CN104302323A (zh)	2012-01-12	2015-01-21	变异生物技术公司	用于治疗病毒感染的组合物和方法
CN104244984B (zh)	2012-01-27	2020-03-31	变异生物技术公司	用于治疗剂的方法和组合物
CN115124628B (zh) *	2021-03-27	2023-03-31	中国科学院昆明植物研究所	一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0283327B1 (fr) *	1987-01-16	1997-06-25	Institut Pasteur	Peptides ayant des propriétés immunologiques de HIV-2
ES2194029T5 (es) *	1988-06-14	2016-10-26	Qiagen Gmbh	Variantes del virus HIV-2

1989
- 1989-10-14 DE DE3934366A patent/DE3934366A1/de active Granted
1990
- 1990-10-12 DE DE59006080T patent/DE59006080D1/de not_active Revoked
- 1990-10-12 WO PCT/EP1990/001729 patent/WO1991005567A1/de not_active Application Discontinuation
- 1990-10-12 DK DK90915992.3T patent/DK0495896T3/da active
- 1990-10-12 EP EP90915992A patent/EP0495896B1/de not_active Revoked
- 1990-10-12 JP JP51473190A patent/JP3152433B2/ja not_active Expired - Fee Related
- 1990-10-12 AT AT90915992T patent/ATE106748T1/de not_active IP Right Cessation
- 1990-10-12 ES ES90915992T patent/ES2055922T3/es not_active Expired - Lifetime
1997
- 1997-11-12 US US08/968,689 patent/US5861243A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP3152433B2 (ja)	2001-04-03
WO1991005567A1 (de)	1991-05-02
DE3934366C2 (da)	1991-11-07
DE3934366A1 (de)	1991-04-18
EP0495896A1 (de)	1992-07-29
ES2055922T3 (es)	1994-09-01
ATE106748T1 (de)	1994-06-15
EP0495896B1 (de)	1994-06-08
US5861243A (en)	1999-01-19
DE59006080D1 (de)	1994-07-14
JPH05505389A (ja)	1993-08-12

Publication	Publication Date	Title
DK0495896T3 (da)	1994-10-10	Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel
ATE135747T1 (de)	1996-04-15	Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
FI102382B1 (fi)	1998-11-30	Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
DE69630457D1 (de)	2003-11-27	Verbindungen zur immunotherapie und diagnose von tuberkulose
CA2596274A1 (en)	1997-01-23	Recombinant mva virus, and the use thereof
DE69536039D1 (de)	2010-02-11	Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
DK694687A (da)	1988-07-01	Hidtil ukendte oligosaccharider, immunogener og vacciner og fremgangsmaader til fremstilling af disseoligosaccharider, immunogener og vacciner
NO912825D0 (no)	1991-07-18	Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
GR3022248T3 (en)	1997-04-30	Oligonucleotide sequences for amplification of type HIV-2 and SIV retroviruses genomes and their application to in-vitro diagnostic of infections caused by these viruses
HUP0303431A2 (hu)	2004-01-28	PRRS vírus élő legyengített törzsei
BR9608894A (pt)	1999-12-07	Produtos extracelulares abundantes e processos para suas producões e usos
ES426215A1 (es)	1976-11-16	Procedimiento para preparar una vacuna de adenovirus bovi- nos vivos.
EP0236977A3 (en)	1989-05-03	Bovine virus diarrhea and hog cholera vaccines
NO890565L (no)	1989-02-09	Forhindring og behandling av retroviral sykdom.
FR2600079B1 (fr)	1989-10-20	Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
DK612889A (da)	1990-06-08	Enzym og fremgangsmaade til fremstilling deraf
NZ222766A (en)	1990-09-26	Aids virus antigens: env/gag polypeptides: production by genetic engineering techniques: vaccines, and methods of diagnostic testing
CA2350127A1 (en)	2000-05-18	Avipox vector coding an hiv antigen and a cytokine
ATE143373T1 (de)	1996-10-15	Proteine, vakzine und nucleinsäuren
WO2003073984A3 (en)	2004-11-25	Tat as an immunogen
FR2792639B1 (fr)	2003-06-06	Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
TH23870A (th)	1997-03-05	วัคซีนและวิธีสำหรับการเตรียม